Literature DB >> 15967161

Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor.

Sung-Hee Chang1, Catherine H Liu, Ming-Tao Wu, Timothy Hla.   

Abstract

Prostaglandin E(2) (PGE(2)), a major metabolite of the cyclooxygenase pathway in the mammary gland, induces angiogenesis during mammary tumor progression. To better define the molecular mechanisms involved, we examined the role of the G protein-coupled receptors (GPCR) for PGE(2) in mammary tumor cell lines isolated from MMTV-cyclooxygenase-2 (COX-2) transgenic mice. Expression of the EP2 subtype of the PGE(2) receptor was correlated with the tumorigenic phenotype and the ability to induce vascular endothelial growth factor (VEGF). Overexpression of EP2 by adenoviral transduction into EP2-null cells resulted in the induction of VEGF expression in response to PGE(2) and CAY10399, an EP2 receptor agonist. The induction of VEGF by the EP2 receptor did not require the hypoxia inducible factor (HIF)-1alpha pathway, MAP kinase pathway, or phosphoinositide-3-kinase/Akt pathway, but required the cAMP/protein kinase A pathway. These results suggest that EP2 receptor is a critical element for PGE(2) mediated VEGF induction in mouse mammary tumor cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967161     DOI: 10.1016/j.prostaglandins.2004.12.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  18 in total

Review 1.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 2.  Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

Authors:  G O'Callaghan; A Houston
Journal:  Br J Pharmacol       Date:  2015-10-26       Impact factor: 8.739

3.  Role of cytosolic phospholipase A(2) in retinal neovascularization.

Authors:  Joshua M Barnett; Gary W McCollum; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

4.  Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction.

Authors:  Emily L Messina; Jeffrey Nienaber; Mani Daneshmand; Nestor Villamizar; Jude Samulski; Carmelo Milano; Dawn E Bowles
Journal:  Hum Gene Ther       Date:  2012-08-27       Impact factor: 5.695

Review 5.  Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection.

Authors:  Jianxiong Jiang; Ray Dingledine
Journal:  Trends Pharmacol Sci       Date:  2013-06-21       Impact factor: 14.819

6.  Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.

Authors:  Laura von der Emde; Diane Goltz; Stefan Latz; Stefan C Müller; Glen Kristiansen; Jörg Ellinger; Isabella Syring
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

7.  The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways.

Authors:  Kyung-Soo Chun; Huei-Chen Lao; Robert Langenbach
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

8.  miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF).

Authors:  Jinqiang Zhang; Chang Han; Hanqing Zhu; Kyoungsub Song; Tong Wu
Journal:  Am J Pathol       Date:  2013-05       Impact factor: 4.307

9.  PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.

Authors:  Maozhen Tian; William P Schiemann
Journal:  FASEB J       Date:  2009-11-06       Impact factor: 5.191

Review 10.  Bioactive lysolipids in cancer and angiogenesis.

Authors:  Yu Hisano; Timothy Hla
Journal:  Pharmacol Ther       Date:  2018-07-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.